What Are Kratom Pills? Effects, Risks, and Legal Status

Kratom pills are capsules or tablets containing powdered leaf material from Mitragyna speciosa, a tropical tree native to Southeast Asia. The pills deliver two key alkaloids, mitragynine and 7-hydroxymitragynine, that interact with the brain’s opioid receptors in ways that produce stimulant effects at low doses and sedative, pain-relieving effects at higher ones. Kratom occupies a strange regulatory gray zone: it is not FDA-approved for any medical use and is banned in a handful of U.S. states, yet it remains legally sold in most of the country as a dietary supplement or botanical product.

What Is Actually Inside a Kratom Pill

Most kratom pills sold in the United States contain ground-up leaves of the kratom tree, sometimes labeled by vein color (red, green, white) that supposedly reflects different effects. The primary active ingredient is mitragynine, which typically makes up between 1 and 6 percent of leaf material. A second alkaloid, 7-hydroxymitragynine, is present in much smaller amounts, usually between 0.01 and 0.04 percent of leaf content.¹ Despite its low concentration, 7-hydroxymitragynine is the more pharmacologically potent compound, with roughly ten times the painkilling strength of morphine in animal studies.²

A chemical analysis of over 340 kratom products available in the United States found that the vast majority were whole-leaf products rather than concentrated extracts, and their alkaloid profiles matched what you would expect from plain kratom leaf material. That same study found no evidence of adulteration with illicit or prescription drugs in the products tested. Based on self-reported use patterns, the average person consumed about 31 mg of mitragynine per dose, with daily intake ranging from roughly 50 to 135 mg.³ Those numbers matter because effect and risk both scale with how much you take and how often.

How Kratom Affects the Brain

Both mitragynine and 7-hydroxymitragynine act as partial agonists at mu-opioid receptors, the same receptors activated by drugs like morphine and fentanyl. They also interact with kappa- and delta-opioid receptors, behaving more as blockers there.⁴ The word “partial” is doing real work in that sentence. Unlike full opioid agonists such as heroin or fentanyl, which flood the receptor with maximum activation, kratom’s alkaloids produce a weaker ceiling effect. This partial activity is one reason kratom’s painkilling and euphoric effects are generally less intense than those of prescription opioids, and it may contribute to a lower risk of fatal respiratory depression when kratom is used alone.

There is also an interesting wrinkle in how these alkaloids signal inside the cell. Both mitragynine and 7-hydroxymitragynine preferentially activate a signaling pathway called the G-protein pathway over an alternative one called the beta-arrestin pathway.² Researchers have theorized that this “biased” signaling profile could mean fewer side effects like constipation and slowed breathing compared to traditional opioids. That hypothesis has driven interest in developing kratom-derived drugs, though clinical proof in humans is still lacking.

The Dose-Dependent Split Between Stimulant and Opioid Effects

One of the most distinctive things about kratom is how dramatically its effects shift depending on the amount taken. At low doses, it acts more like a stimulant: people report increased energy, alertness, and sociability. At higher doses, the opioid-like properties take over, producing sedation, euphoria, and pain relief.⁵ This isn’t just anecdotal; it reflects the pharmacology. At lower concentrations, mitragynine’s effects on adrenergic and serotonergic receptors appear more prominent, while at higher concentrations its opioid receptor activity dominates.

This biphasic quality helps explain why kratom attracts such different user groups. Some people take small amounts in capsule form as a productivity or mood boost, treating it like a strong cup of coffee. Others use larger doses specifically for pain or to manage opioid withdrawal symptoms. The lack of standardized dosing on product labels makes this split harder to navigate, because the actual alkaloid content in a given capsule can vary considerably between brands and even between batches from the same vendor.

Why People Use Kratom

Surveys of regular kratom users paint a consistent picture. In one large online survey, the most commonly reported reason for use was pain relief, endorsed by about half of respondents. Roughly a fifth reported using kratom for anxiety, PTSD, or depression. About one in ten used it to increase energy or focus, and another tenth used it specifically to reduce opioid use or manage withdrawal.⁶ Qualitative research echoes these themes, with users describing kratom as helpful for pain management, mood elevation, anxiety reduction, and opioid withdrawal.⁷

What stands out is how much of kratom’s popularity is driven by self-medication for conditions that have conventional treatments. Many users report turning to kratom after unsatisfying experiences with prescription painkillers, antidepressants, or anti-anxiety medications. The appeal is partly pharmacological and partly practical: kratom is legally available without a prescription in most states, relatively cheap, and perceived by users as “natural” and therefore safer than pharmaceuticals. Whether that perception of safety is warranted is a more complicated question.

Dependence, Tolerance, and Withdrawal

Because kratom acts on opioid receptors, it carries a real risk of physical dependence. Research on regular users suggests that both withdrawal symptoms and signs of a kratom use disorder become more likely as dosing frequency increases. The relationship was stronger for how often people dosed than for how much they took at each sitting, meaning someone who takes small amounts five times a day may develop dependence faster than someone who takes a larger dose once daily.⁸

Withdrawal symptoms from kratom look a lot like mild to moderate opioid withdrawal. Physical symptoms commonly include muscle pain and spasms, trouble sleeping, runny nose and watery eyes, hot flashes, fever, decreased appetite, and diarrhea. Psychological symptoms include restlessness, tension, anger, sadness, and nervousness.⁹ The severity is generally described as milder than withdrawal from stronger opioids, but it can still be deeply uncomfortable and is a significant barrier for people who want to stop using kratom.

That said, the picture isn’t all-or-nothing. Some regular users apparently use kratom without developing problematic dependence, and when dependence does develop, the most common symptoms tend to be withdrawal and craving rather than the kind of severe functional impairment seen with heroin or fentanyl dependence.⁸

Serious Health Risks and Toxicity

Poison control centers in the United States saw a dramatic rise in kratom-related calls over the 2010s. Between 2010 and 2015, calls increased tenfold, from 26 to 263 in a single year. Among those exposures, about 42 percent were classified as moderate (requiring some form of treatment), and about 7 percent were classified as major or life-threatening. Common symptoms included rapid heart rate, agitation, drowsiness, nausea, and high blood pressure.¹⁰ A broader analysis of poison center data from 2011 to 2017 found that among kratom-only exposures, over 86 percent resulted in at least one clinical effect, with agitation and rapid heart rate being the most common.¹¹

Beyond acute poisoning, kratom has been linked to liver injury. Case reports describe cholestatic liver damage, acute liver failure, seizures, and in rare instances, death.¹² These events appear to be uncommon relative to the millions of people who use kratom, but they are difficult to predict and there is no reliable way to identify who is at risk beforehand.

Deaths Linked to Kratom Almost Always Involve Other Substances

This is where the risk picture gets both more nuanced and more alarming. A review of 156 deaths associated with kratom found that the typical case was a young white male with a history of drug use. In 87 percent of those deaths, multiple substances were detected. Mitragynine alone was identified as the implicated cause in only about 23 percent of cases.¹³ A smaller autopsy study of opioid overdose deaths where kratom was detected found that every case also tested positive for at least one other substance, with fentanyl present in three out of four cases.¹⁴

The practical takeaway is that while kratom alone appears to have a lower lethality profile than full opioid agonists, mixing it with other substances, especially fentanyl, benzodiazepines, or alcohol, substantially raises the danger. Many people who use kratom also have histories of using other drugs, which makes it harder to untangle kratom’s independent contribution to fatal outcomes. It also means that the population most attracted to kratom for opioid substitution is the same population most at risk of dangerous poly-substance exposure.

Contamination Is a Real Problem

Because kratom is sold as a botanical supplement rather than a regulated drug, quality control is inconsistent. Multiple studies have found that some kratom products contain concerning levels of heavy metals, particularly lead and arsenic. Non-extract products like powders, capsules, and tablets tend to have higher concentrations of these contaminants than liquid extracts.¹⁵ Research from FDA testing and independent labs has confirmed that many products on the U.S. market are contaminated with potentially hazardous levels of lead.¹⁶ For someone taking kratom daily, these exposures can exceed established safety thresholds over time.

Vendor marketing doesn’t help matters. An evaluation of online kratom vendors who claim to follow Good Manufacturing Practices found that while their websites were fairly clear about shipping and purchasing logistics, the health information they provided scored poorly on quality assessments. Information on kratom’s potential risks was particularly inadequate.¹⁷ This means that even consumers who try to buy from “reputable” vendors are getting an incomplete picture of what they are putting in their bodies.

Drug Interactions Worth Knowing About

If you take kratom alongside prescription medications, the interaction risk is not theoretical. Mitragynine is a relatively potent inhibitor of CYP3A, an enzyme system in your gut and liver responsible for metabolizing a wide range of drugs. A clinical study in humans found that kratom primarily inhibited this enzyme in the intestine, which could raise blood levels of medications broken down by the same pathway.¹⁸ CYP3A handles the metabolism of many common medications, including certain blood thinners, anti-seizure drugs, immunosuppressants, and some HIV medications. Taking kratom with these drugs could effectively increase the dose your body absorbs, potentially pushing side effects into dangerous territory.

Kratom also acts as a substrate for the same enzyme systems, meaning that other drugs can alter how your body processes kratom itself.¹⁹ The practical concern here is bidirectional: kratom changes how you metabolize other drugs, and other drugs change how you metabolize kratom. If you are taking any prescription medication, mixing in kratom introduces unpredictability that most physicians would strongly advise against.

Legal Status in the United States

Kratom’s legal status is a patchwork. At the federal level, it is not a controlled substance and is not FDA-approved for any medical use. Kratom is primarily marketed as a dietary supplement, which means it does not undergo the safety and efficacy review required of pharmaceuticals. As of recent legislative tracking, six states have placed mitragynine and 7-hydroxymitragynine on Schedule I, effectively banning kratom. Meanwhile, thirteen states have enacted versions of the Kratom Consumer Protection Act, which regulates rather than bans kratom by setting standards for purity, labeling, and age restrictions on purchase. Several other states impose minimum age requirements without broader regulatory frameworks.²⁰

The federal regulatory history is unusual. In 2016, the DEA proposed emergency scheduling of kratom’s active alkaloids as Schedule I substances, which would have made possession a federal crime. After pushback from consumers, researchers, and members of Congress, the DEA took the rare step of withdrawing its proposal. The FDA then requested that the DEA permanently schedule the compounds in 2017, but the DEA did not act on that request, and the Department of Health and Human Services eventually rescinded the FDA’s recommendation after reviewing the scientific evidence.²⁰ The result is that kratom exists in a regulatory limbo: the FDA has repeatedly warned against its use, but the federal government has not moved to ban it.

Kratom in Southeast Asia

Kratom has been used in traditional medicine across Southeast Asia for centuries, where chewing the fresh leaves was a common practice among laborers seeking energy and pain relief. Despite this long cultural history, several countries in the region banned it. Thailand, for instance, criminalized kratom in 1943, creating lasting tension between government authorities and southern Thai communities that viewed the plant as a traditional remedy rather than a drug.²¹ Thailand eventually decriminalized kratom in 2021 and removed it from its narcotics list, reflecting a broader shift toward acknowledging its cultural role while attempting to regulate rather than prohibit its use. Malaysia and Myanmar, by contrast, still maintain restrictions.

Treatment Options When Kratom Use Becomes Problematic

For people who develop kratom dependence and can’t quit on their own, the best-studied treatment approach borrows from opioid addiction medicine. Multiple case reports and case series have documented successful treatment of kratom use disorder using buprenorphine/naloxone (the combination marketed as Suboxone), the same medication used for heroin and prescription opioid dependence.²² The largest published case series on long-term buprenorphine treatment for kratom dependence concluded that it appeared effective at managing withdrawal and supporting abstinence.²³

This is still early-stage evidence. There are no large randomized trials comparing different treatment strategies specifically for kratom dependence, and most of the published literature consists of individual case reports or small series.²⁴ If you or someone you know is struggling with kratom dependence, the reasonable first step is talking to a physician familiar with addiction medicine, since the withdrawal profile overlaps enough with opioid withdrawal that established treatment protocols can be adapted.

Effects on Cognition

Concerns about long-term cognitive effects of kratom are understandable but, so far, the evidence is surprisingly thin. One study comparing regular kratom users to non-users found that higher-consumption users (more than three glasses of kratom tea daily) showed impairment on a visual memory and learning task. However, on broader tests covering motor function, attention, executive function, and other memory domains, kratom users performed comparably to controls.²⁵ This suggests that any cognitive effects are likely subtle and domain-specific rather than a blanket cognitive decline, at least at the doses commonly used. But the research base is small, and no one has followed heavy users over many years to see whether deficits accumulate.

Pregnancy and Newborns

One risk that gets less attention than it deserves involves pregnant women who use kratom. Because kratom’s alkaloids cross the placenta, regular use during pregnancy can result in neonatal abstinence syndrome, the same withdrawal condition seen in babies born to mothers who use opioids. At least one documented case involved a full-term newborn whose mother used kratom chronically throughout pregnancy; the infant required opioid treatment for withdrawal symptoms after birth.²⁶ Systematic data on this issue are scarce, in part because many healthcare providers don’t ask about kratom use and standard drug screens don’t test for it. For anyone who is pregnant or planning to become pregnant, the absence of safety data alone is a strong reason to avoid kratom.